The insulin receptor has been proposed as a candidate gene for the inherited defect in Type 2 (non-insulindependent) diabetes mellitus and we therefore studied three restriction fragment length polymorphic sites, two revealed with the enzyme Sstl and one by Rsal, using two insulin receptor cDNA probes in 131 Caucasian Type 2 diabetic patients and 94 control subjects. The frequency of the six alleles studied did not differ significantly between the two groups. However, one allele, a 6.2 kilobase Rsal fragment (R + ), was found more frequently in those diabetic subjects (n = 48) with a positive family history of diabetes (R + frequency = 0.48) compared to those diabetic subjects (n = 63) with a negative family history (R + frequency= 0.34, p < 0.05). These results suggest that this polymorphism may be a linkage marker for the genetic defect in a subgroup of Type 2 diabetic patients with a positive family history.
Type 2 (non-insulin-dependent) diabetes mellitus has strong genetic determinants as shown by high concordance for the disease in monozygotic twins [1] . The disease is unlikely to be monogenic as its inheritance does not follow a Mendelian pattern. While the precise genetic defects have yet to be identified, insulin resistance has been suggested as the primary feature of Type 2 diabetes [2] , while others propose a defect of the first phase of insulin secretion [3] . The pathogenesis may involve a two-stage process with chronic insulin resistance due to genetic and/or environmental factors as the primary defect, with compensatory hyperinsulinaemia, and then secondary Beta-cell failure in susceptible islet cells giving rise to the diabetic phenotype.
The cellular mechanisms underlying insulin resistance have received intensive study. Attention has focussed on the possible role of insulin receptor defects in determining insulin resistance. This transmembrane glycoprotein consists of two c~-subunits, which contain the insulin binding domain, and two [3-subunits which possess tyrosine kinase and autophosphorylation activity [4] . Mutations of the insulin receptor gene have been reported in rare disorders which are characterised by extreme insulin resistance, for example leprechaunism (Lys460 to Glu in one allele and Gln671 to a stop codon in the other) [5] , and Type A syndrome (insulin resistance, acanthosis nigricans and virilisation) [6] . Insulin receptors isolated from erythrocytes [7] , adipocytes [8] and hepatocytes [9] of Type 2 diabetic patients all show reduced insulin-stimulated tyrosine kinase activity, reversible by insulin therapy, despite normal insulin binding. This post-binding defect of receptor kinase activity appears to be specific for Type 2 diabetes and is not seen in obese non-diabetic subjects who are insulin resistant [10] .
The insulin receptor gene is located on chromosome 19 at 19p13.3-13.2 [11] and is composed of 22 exons and 21 introns spanning a region of greater than 120 kilobase (kb) pairs [12] . Only 10-15% of the insulin receptor genomic sequence is known but the availability of a cloned human insulin receptor cDNA probe [4] and further characterisation of restriction fragment length polymorphisms (RFLP) around this locus [13] make it feasible to study whether inherited structural defects of the insulin receptor are involved in the aetiology of Type 2 diabetes. If a diabetogenic locus were present within or close to the insulin receptor gene, it may be in linkage disequilibrium with an RFLP marker at this site and several population association studies have suggested that variation at this locus may predispose subjects to Type 2 diabetes [14] [15] [16] [17] [18] . In the present study we have examined three polymorphic sites at the insulin receptor locus to see if differences in genotype variants occur between British non-insulin-dependent diabetic and control subjects. , and gave their parental origins as SouthEast England. Their mean ( + SD) age was 65.5 ( + 8.6) years and mean (• body mass index (BMI) was 27.0 (+5.0) kg/m 2, The mean age at diagnosis was 55.9 ( _+ 9.6) years and five patients were receiving insulin but had not begun their therapy until at least 5 years after diagnosis. Fifty-two (42%) of the diabetic subjects gave a positive family history of Type 2 diabetes in at least either one first degree relative or two related second degree relatives. Ninety-four male Caucasian control subjects, with a mean (• age of 55.4 (+7.2) years and mean (• BMI of 25.6 ( _+ 2.6) kg/m 2, were recruited from a health screening clinic on the basis of a negative personal and family history of diabetes, and a fasting blood glucose of less than 6 mmol/1. Seventy-three (61%) of the diabetic subjects and 52 (55%) of control subjects had a BMI greater than 25 kg/m% All subjects gave informed consent to the studies which were approved by the hospital ethical committee.
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DNA analysis
DNA was extracted from 10 ml whole blood as previously described [20] . Digestion of 8 btg DNA was carried out with 30 U of Sstl or Rsal restriction endonuclease (BRL, Cambridge, UK) according to the manufacturer's instructions. Some samples were not available for digestion with Rsal. The resulting fragments were separated by electrophoresis in 0.85% agarose gels, denatured and blotted onto nylon membranes (Hybond-N, Amersham International, Amersham, UK) by the method of Southern. HindIII digests of lambda DNA were used as size markers. Blots were hybridised with 3;p-labelled insulin receptor probe for 48 h at 42~ in 50% formamide and then washed to a final stringency of 0.2x SSC/0.1% SDS at 62~ Fragments were visualised by autoradiography at -70~ using Hyperfilm-MP (Amersham International).
Construction of probes
Probes were prepared from a 4.3 kb eDNA human insulin receptor probe (kindly donated by Dr. A. Ullrich, Genentech, San Francisco, Calif., USA) extending from base pair 1013 to the 3' end, which was cloned in pUC 12. This probe was digested with Pstl to yield a 1.6 kb probe (P1.6) covering base pairs 2744-4343 of the eDNA covering exons 15 to 22 containing most of the [3-subunit including the tyrosine kinase domain, and with Bgll to give a 1.3 kb probe (B1.3) extending from base pairs 1601-2963 of the eDNA covering exons 8 to 16 [13] (Fig. 1) . These probes were labelled with 32p by random priming [21] .
Statistical analysis
Differences in genotypic and allelic frequencies between groups were assessed using the Z 2 test. 
Results
Two distinct RFLPs were identified in Sstl digests following hybridisation with the probe P1.6, being designated the $1 and $2 loci (Fig.2) . The $1 polymorphism results in fragments of 5.3 kb or 5.8 kb, the alleles being nominated as $1 + and $1 -, respectively in accordance with convention [13, 22] (Fig.2) . BamH1, Taql, Xbal, Pvu11 and X m n l all detected di-allelic polymorphisms with bands 0.5 kb apart using the probe P1.6, and individual genotypes at these loci corresponded exactly with those of the $1 polymorphism, suggesting that the $1 locus represents a 500 base-pair insertion-deletion polymorphism, as suggested previously and which has been localised to the 14th intron ( Fig. 1 ) [22] . The $2 polymorphic locus is characterised by the presence of a 9.4 kb ($2 + ) fragment or of 7.0 and 2.4 kb ($2 -) fragments (Fig. 2) . This polymorphism appears to be caused by the presence ($2 + ) or absence ($2 -) of an Sstl site 2.4 kb from one end of the 9.4 kb fragment. The probe B1.3 also detected the S1 polymorphism but not the $2 polymorphism. The $1 and $2 RFLPs appear to correspond with those described previously [13, 14, 16, 23] . A single RFLP was detected with Rsal using the probe B1.3, which was characterised by bands of 6.8 kb or 6.2 kb, designated R -and R +, respectively according to convention [13] (Fig.2) . A summary of the genotype frequencies at the S1, $2 and Rsa RFLP sites in the diabetic and control subject groups is shown in Table 1 . The genotype distribution in the control subject group at all three polymorphic loci conformed to Hardy-Weinberg proportions. Within the diabetic subject group, there were no significant differences with regard to genotype frequency at all three RFLP sites studied between males and females. There were no overall significant differences in the frequency of any genotype or allele between the diabetic and control subjects at any of the three RFLP sites examined.
As any genetic marker for Type 2 diabetes is likely to be more prevalent in those subjects who have a strong family history of diabetes, we divided the diabetic subject group into those who gave a good positive family history and those who had no family history of diabetes. There was no difference in the allele frequencies at the two polymorphic Sstl sites between the two diabetic groups but in those diabetic subjects with a positive family history the R + (6.2 kb) allele was significantly more common than in those with a negative family history (Z2= 4.31, dr= 1, p < 0.05) ( Table 2) . We also examined whether any allele was associated with obesity because the genetic predisposition to Type 2 diabetes may express itself more clearly in a subgroup of obese subjects. The frequency of the six alleles within the subgroups of overweight (BMI > 25 kg/m 2) and lean diabetic patients and overweight and lean control subjects is also shown in Table 2 . There were no significant differences in allele frequencies at any of the three polymorphic sites when comparing these subgroups in both diabetic and control groups.
Haplotypes were determined from analysis of individuals who were homozygous for at least one RFLP to determine if a particular combination of RFLPs, rather than single alleles, associated with the diabetic phenotype. There was no significant association of any haplotype with the diabetic phenotype. The observed haplotype frequencies for each pair of RFLPs was not significantly different by Z 2 analysis from that expected from the respective allele frequencies at each RFLP site, thus making strong linkage disequilibrium between alleles unlikely (data not shown).
Discussion
Our results show a increased frequency of the R + (6.2 kb) allele in those Type 2 diabetic subjects with a positive family history of Type 2 diabetes compared to those without. It is probable that any linkage marker for Type 2 to BMI < 25 kg/m 2 and > 25 kg/m 2 respectively, n = number of chromosomes studied. a R + allele frequency diabetic subjects with positive family history vs diabetic subjects with negative family history, Z 2 = 4.31, df = 1, p < 0.05; all other differencesp > 0.05 diabetes would be more likely to be found in a subgroup with a positive family history. Population association studies between control subjects who give no family history and diabetic subjects with a positive family history may be more likely to yield results for an aetiological locus.
The results from our study are at variance with two previous studies that reported an association of the S1-(5.8 kb) allele with Type 2 diabetes in Caucasian populations. The differing conclusions from the two previous studies and this study is due to a difference in the $1 -allele frequency between the control populations, being 0.05 and 0.06 in McClain's and Trembath's studies whereas we found it to be 0.12. As there appears to be no differences between the control populations with regard to average age and BMI, a possible explanation for this allele frequency difference is heterogeneity between our English Caucasian population and a more genetically diverse North American Caucasian population. Other published frequencies of the $1 -allele in Caucasian control population report values close to ours [13, 23, 24] .
Studies in other racial groups have produced conflicting results in looking for association between RFLPs at the insulin receptor locus and Type 2 diabetes. In a preliminary report [15] , McGitl et al. reported a weak association of the $1 + (5.3 kb) allele with diabetes in an American Black population. In a study of six candidate genes in an American Chinese population [17] , a haplotype X2R2K2 of the insulin receptor was found significantly less frequently in the diabetic subject group than in the control population, suggesting that in that population some variation at the insulin receptor may contribute to protection from the development of the diabetic phenotype. A recent report from a study of Mexican Americans has also shown a slightly increased "odds ratio" for Type 2 diabetes in subjects homozygous for a 3.4 kb allele detected with the enzyme Rsal I18]. This 3.4 kb Rsal fragment has only been observed in Pima Indians [13] and Mexican Americans [18] and was not found in any of our 164 subjects genotyped at this locus. However, in a study of Punjabi Sikhs [24] no association was found between diabetes and two RFLP markers detected with the enzymes BgllI and BamH1, the latter RFLP corresponding to the S1 RFLP in the present study. We have previously found no association between the two Sstl insulin receptor RFLPs and Type 2 diabetes in a Japanese population [25] . Studies of Caucasian [26] and Black American [27] diabetic pedigrees found linkage between the insulin receptor and diabetes to be unlikely.
Clear racial differences in insulin receptor allele frequencies exist [13, 24, 25] and an association of one allele of an RFLP with Type 2 diabetes in one population but not in another may simply reflect differing evolutionary histories of the RFLP between the two populations, and still provide a useful linkage marker. Similarly, because non-insulin-dependent diabetes is probably a heterogeneous disorder, linkage markers might only be identified in a subgroup of Type 2 diabetic subjects.
